Jerusalem, 27 October, 2025 (TPS-IL) — Israeli cell therapy company Kadimastem Ltd. has signed a memorandum of understanding with fellow Israeli firm TargetGene Biotechnologies to jointly develop next-generation gene-edited cell therapies. The collaboration combines Kadimastem’s stem-cell platforms, including AstroRx for ALS and IsletRx for diabetes, with TargetGene’s precision gene-editing technology.
The partnership will continue under the combined company, NewCelX, following Kadimastem’s anticipated merger with Swiss biopharmaceutical NLS Pharmaceutics.
Kadimastem executives said the alliance aims to create safer, more effective, and commercially viable regenerative therapies for patients worldwide.